LBSP Favicon

Synthetic antibodies that could transform drug development

What if you could design something that acts like an antibody, but cheaper, more stable, and made entirely with chemistry? Two LACDR researchers, Sebastian Pomplun and Matthias Barz, teamed up […]

What if you could design something that acts like an antibody, but cheaper, more stable, and made entirely with chemistry?

Two LACDR researchers, Sebastian Pomplun and Matthias Barz, teamed up to do just that. By merging peptide synthesis with polymer chemistry, they developed synthetic molecules that mimic the size, shape, and function of antibodies, without the cold storage, high production costs, or immune side effects.

These ‘bottlebrush-like’ nanoscale particles are tough, modular, and ready for next-gen therapies. The concept worked from the very first experiment. The potential? Faster drug development, better patient access, and new pathways for targeting disease.

Read the full story here.

Related posts

Open Day Recap

Open Day Recap

𝗪𝗵𝗮𝘁 𝗵𝗮𝗽𝗽𝗲𝗻𝘀 𝘄𝗵𝗲𝗻 𝗺𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝟭𝟱 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗮𝗻𝗱 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗼𝗿𝗴𝗮𝗻𝗶𝘀𝗮𝘁𝗶𝗼𝗻𝘀 𝗼𝗽𝗲𝗻 𝘁𝗵𝗲𝗶𝗿 𝗱𝗼𝗼𝗿𝘀 𝘁𝗼 𝘁𝗵𝗲 𝗽𝘂𝗯𝗹𝗶𝗰? You get an Open Day that brings together over 2,400 visitors, families, students,...